Key result
SCH 34826 significantly reduced blood pressure and enhanced urine volume output (2.78 vs. 1.27 ml/100 g/3 hr, p<0.05) in deoxycorticosterone acetate-salt hypertensive rats.
Why the study?
Does SCH 34826 reduce blood pressure and potentiate the effects of atrial natriuretic factor in hypertensive rat models?
Population
Conscious spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats
Comparison
SCH 34826 alone or with atrial natriuretic factor vs Vehicle-control rats
Design
Preclinical
Follow-up
Up to 5 days
Authors
Loading...
Hypothesis-generating in hypertensive rat models; leaves open translation to human therapy.
Does SCH 34826 reduce blood pressure and potentiate the effects of atrial natriuretic factor in hypertensive rat models?
p-value: p=<0.05
Neutral endopeptidase inhibition with SCH 34826 reduces blood pressure and potentiates atrial natriuretic factor in hypertensive rat models, suggesting a potential approach for treating hypertension.
Sybertz et al. (1990) studied Hypertension. SCH 34826 vs. Vehicle was evaluated on Blood pressure and urine volume output (p=<0.05). SCH 34826 significantly reduced blood pressure and enhanced urine volume output (2.78 vs. 1.27 ml/100 g/3 hr, p<0.05) in deoxycorticosterone acetate-salt hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: